Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34473961 | 0.80 | POLB (0.40) | ALDH1A1TSHRPOLBMAPTHTT | |
| SCHEMBL22405796 | 0.80 | ALDH1A1 (0.38) | ALDH1A1TSHRPOLBLMNAAURKA | |
| SCHEMBL4367412 | 0.80 | ALDH1A1 (0.34) | ALDH1A1TSHRPOLBMAPTAURKA | |
| SCHEMBL27961325 | 0.78 | P2RX7 (0.36) | ALDH1A1TSHRPOLBAURKAKDM4E | |
| SCHEMBL27961324 | 0.77 | ALDH1A1 (0.32) | ALDH1A1TSHRPOLB | |
| SCHEMBL3852882 | 0.77 | KIF11 (0.43) | ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL25282800 | 0.76 | ALDH1A1 (0.34) | ALDH1A1TSHRPOLBAURKACYP11B2 | |
| SCHEMBL4369849 | 0.76 | ALDH1A1 (0.35) | ALDH1A1TSHRPOLBMAPTCYP11B2 | |
| SCHEMBL24112327 | 0.76 | ALDH1A1 (0.34) | ALDH1A1TSHRPOLBMAPTAURKA | |
| SCHEMBL3852012 | 0.76 | ALDH1A1 (0.34) | ALDH1A1TSHRPOLBMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291523-B2 | LXR modulators with bicyclic core moiety | ORSOBIO, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20240317726-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO, INC. | 2024-09-26 | — | — | US | disclosed |
| US-11970484-B2 | LXR modulators with bicyclic core moiety | ORSOBIO, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| EP-3533797-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-20 | — | — | EP | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| EP-3814331-B9 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO INC (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3814331-B1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO INC (US) | 2023-06-14 | — | — | EP | disclosed |
| US-11618747-B2 | LXR modulators with bicyclic core moiety | ORSOBIO, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20210147398-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX-FXR GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| EP-3814331-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | Phenex-FXR GmbH (DE) | 2021-05-05 | — | — | EP | disclosed |
| US-20140235615-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-21 | — | — | US | disclosed |
| US-20140228352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
| US-8722660-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-13 | — | — | US | disclosed |
| US-20130029969-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-31 | — | — | US | disclosed |
| EP-2540728-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2013-01-02 | — | — | EP | disclosed |
| CN-102844320-A | Heterocyclic compounds | TAKEDA PHARMACEUTICAL | 2012-12-26 | — | — | CN | disclosed |
| EP-2048142-A2 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2009-04-15 | — | — | EP | disclosed |
| EP-1382603-B1 | NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-7074801-B1 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | EISAI CO., LTD. (JP) | 2006-07-11 | — | — | US | disclosed |
| EP-1382603-A1 | NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317726-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NCOA3 | ALDH1A1 4262/4885TSHR 413/4885POLB 4749/4885 |
| US-11618747-B2 | LXR modulators with bicyclic core moiety | NR1H2, NR1H3, NR1H4 | ALDH1A1 3798/4885TSHR 364/4885POLB 4556/4885 |
| US-20130029969-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | ALDH1A1 71/4885TSHR 3819/4885POLB 2206/4885 |
| US-12291523-B2 | LXR modulators with bicyclic core moiety | NR1H2, NR1H3, NR1H4 | ALDH1A1 4042/4885TSHR 362/4885POLB 4720/4885 |
| US-11970484-B2 | LXR modulators with bicyclic core moiety | NR1H2, NR1H3, NR1H4 | ALDH1A1 3798/4885TSHR 364/4885POLB 4556/4885 |
| US-20210147398-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | ALDH1A1 3993/4885TSHR 424/4885POLB 4648/4885 |
| US-20140228352-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | ALDH1A1 71/4885TSHR 3819/4885POLB 2206/4885 |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | ALDH1A1 3993/4885TSHR 424/4885POLB 4648/4885 |
| US-20140235615-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | ALDH1A1 71/4885TSHR 3819/4885POLB 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.